Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Hepatology

Volumn 62, Issue 2, 2015, Pages 409-416

  Ahmad, Tariq ^a   Yin, Philip ^b   Saffitz, Jeffrey ^c   Pockros, Paul J ^d   Lalezari, Jacob ^e   Shiffman, Mitchell ^f   Freilich, Bradley ^g   Zamparo, Joann ^b   Brown, Kyle ^b   Dimitrova, Dessislava ^b   Kumar, Monica ^b   Manion, Doug ^b   Heath Chiozzi, Margo ^b   Wolf, Robert ^b   Hughes, Eric ^b   Muir, Andrew J ^a   Hernandez, Adrian F ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SCRIPPS CLINIC   (United States)

^e Quest Clinical Research   (United States)

^f Bon Secours Health System   (United States)

^g Kansas City Gastroenterology and Hepatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BMS 986094; BRAIN NATRIURETIC PEPTIDE; DACLATASVIR; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; PROCHLORPERAZINE; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; GUANOSINE PHOSPHATE; INX 08189; PROTEINASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART ATRIUM ENLARGEMENT; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT BUNDLE BRANCH BLOCK; HEPATITIS C; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG EDEMA; MALE; MUSCLE FIBRIL; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINUS BRADYCARDIA; T WAVE INVERSION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; FOLLOW UP; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ADULT; AGED; ANTIVIRAL AGENTS; CARDIOMYOPATHIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUANOSINE MONOPHOSPHATE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84938201899     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27488     Document Type: Article

References (18)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
3. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-1917.
4. De Clercq E. The race for interferon-free HCV therapies: a snapshot by the spring of 2012. Rev Med Virol 2012;22:392-411.
5. Sherman RE, Li J, Shapley S, Robb M, Woodcock J. Expediting drug development-the FDA's new "breakthrough therapy" designation. N Engl J Med 2013;369:1877-1880.
6. Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 2011;55:1843-1851.
7. Rodriguez-Torres M, Lawitz E, Hazan L, Barry A, Wenzel A, Alam J, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naïve genotype-1 chronic HCV patients. Presented at 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, November 4-8, 2011. Hepatology 2011;54:535A.
8. Bristol-Myers Squibb. BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in treatment-naïve HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: week 12 results. Available at: http://www.bms.com/Documents/cbt/AI472-003_poster.pdf. Updated 2012. Accessed November 19, 2013.
9. Bristol-Myers Squibb. BMS discontinued investigational programs: program details. Bristol- Available at: http://www.bms.com/clinical_trials/discontinued/Pages/Program_Details.aspx. Accessed August 29, 2014.
10. Davies MH, Graziano MJ, Sanderson TP. BMS-986094: nonclinical investigative studies on a nucleoside analog intended for treatment of hepatitis C virus infection [abstract 849]. Presented at the 53rd Annual Meeting and ToxExpo, Phoenix, AZ, March 24-27, 2014. The Toxicologist 2014;138:220.
11. VanVleet TR, Simic D, Horn KH. BMS-986094: transcriptional profiling in monkeys and mice [abstract 854]. Presented at the 53rd Annual Meeting and ToxExpo, Phoenix, AZ, March 24-27, 2014. The Toxicologist 2014;138:221.
12. Gill MW, Hennan JK, Buchanan LV, et al. BMS-986094: repeat-dose oral cardiovascular (CV) safety pharmacology study in monkeys [abstract 851]. Presented at the 53rd Annual Meeting and ToxExpo, Phoenix, AZ, March 24-27, 2014. The Toxicologist 2014;138:220.
13. Kwagh J, Storck C, Shi H, Huang M, Levesque PC, Flint O. BMS-986094: potential cytotoxicity in differentiated human cardiomyocytes [abstract 856]. Presented at the 53rd Annual Meeting and ToxExpo, Phoenix, AZ, March 24-27, 2014. The Toxicologist 2014;138:221.
14. Stoltz JH, Stern JO, Huang Q, Seidler RW, Pack FD, Knight BL. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Toxicol Pathol 2011;39:496-501.
15. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32.
16. U.S. Food and Drug Administration (FDA). Potential signs of serious risks/new safety information identified from the FDA Adverse Event Reporting System (FAERS) (formerly AERS). Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082196.htm. Updated July 10, 2014. Accessed August 29, 2014.
17. Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012;126:2749-2763.
18. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008;59:1-12.